Omalizumab treatment is considered for both adults and children aged ≥6 years with serum total IgE levels of 30–150 IU/ml and poorly controlled severe atopic asthma despite treatment at step 5, according to the GINA guidelines. This evidence concerns the gene IGHE and atopic asthma.